Strides Pharma FY26 Results: Dividend, Demerger Gain

Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, along with a final dividend of ₹5 per share.
Consolidated FY26 revenue rose to ₹50,094 million with continuing operations PAT at ₹5,745 million, while standalone revenue was ₹21,801 million with PAT of ₹1,836 million.
Results include a significant ₹31,881 million gain from the April 2024 demerger of the CDMO and Softgel business, treated as a discontinued operation.
Auditor B S R & Co. LLP issued an unmodified opinion on both standalone and consolidated results for FY26.